Interchangeable Insulin: One Step Forward, Two Steps Back?

US FDA’s update on the process for converting insulin (and a dozen other complex molecules) from “drug” to “biologic” applications is an important milestone, but framing it as progress towards cheaper medicines for diabetics is a bet of stretch.